Jonathan Strober

1 week ago | ajmc.com | Maggie L. Shaw |Jonathan Strober

Jonathan Strober, MD, is a pediatric neurologist, director of clinical services for child neurology and of the Muscular Dystrophy Clinic at UCSF Benioff Children's Hospital, and an investigator on the phase 2/3 Vibrance-MG study (NCT05265273), which is evaluating nipocalimab for use in pediatric patients in the US, Japan, Netherlands, and Poland.

3 weeks ago | ajmc.com | Maggie L. Shaw |Jonathan Strober

Nipocalimab (Imaavy; Johnson & Johnson) was approved by the FDA on April 30, 2025, to treat generalized myasthenia gravis in adult patients and pediatric patients 12 years or older who are anti–acetylcholine receptor (AChR) positive or anti–muscle-specific kinase (MuSK) antibody positive, based on data from the phase 3 Vivacity-MG3 study (NCT04951622). This is the first and only FcRn-blocking monoclonal antibody approved to treat these 2 patient populations.